Geelen IGP, Gullaksen SE, Ilander MM, Olssen-Stromberg U, et al. Switching from imatinib to nilotinib plus pegylated interferon-alpha2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Ann Hematol 2023;102:1395-1408.
PMID: 37119314